Increased Survival despite Failure of Transplanted Human Hepatocyte Implantation into Liver Parenchyma of Nude Mice with Repeated Lethal Jo2-Induced Liver Deficiency

Abstract

We recently found that rat hepatocyte transplantation was efficient (liver repopulation: 2.4%) in a sublethal nude mouse model (less than 33% mortality) of repeated liver injury generated using Jo2, a mouse-specific anti-Fas antibody, at sublethal dose of 250 μg/kg for 3 weeks. Genomic analysis of the livers revealed cell cycle blockade and an antiproliferative status of circadian genes, suggesting a selective advantage. By contrast, in the present study, freshly isolated human hepatocyte transplantation performed in the same mouse model resulted in implantation of less than 6,000 cells per liver (about 0.006% repopulation) in all animals. Genomic analysis of nude mouse livers revealed a lack of P21 upregulation, while a signature of stimulation of liver regeneration was observed, including upregulation of early response genes and upregulation of circadian genes. When we translated this sublethal model to a lethal model (65% mortality) by increasing the Jo2 repeated doses to 375 μg/kg, human hepatocyte engraftment was still very low; however, animal mortality was corrected by transplantation (only 20% mortality). Genomic findings in livers from the mice of the lethal Jo2 transplanted group were similar to those of the sublethal Jo2 transplanted group, that is, no selective advantage genomic signature and signature of mouse liver regeneration. In conclusion, transplanted human hepatocytes acted as if they modified nude mouse liver responses to Jo2 by stimulating liver regeneration, leading to an increased survival rate.

Keywords

Human hepatocytes Jo2 Hepatocyte transplantation Genomic analysis Nude mouse

Introduction

In the current context of lack of organ donors, hepatocyte transplantation could be an alternative to liver transplantation (9,11,36,37). Efficient hepatocyte transplantation could allow a transient mainstay of the diseased or partial resected liver to detoxify the organism during the time course of liver regeneration or, in case no liver regeneration occurs, to wait for liver donation for transplantation (18,41).

Animal models of liver deficiency represent an important stage before performing hepatocyte transplantation in humans with the aim of treatment of clinical pathologies. Difficulties reside in developing animal models that not only present liver injury mimicking clinical pathologies, but also predict the response of human liver to human allogeneic hepatocyte transplantation.

Recently, we developed a nude mouse model with repeated acute liver deficiency, by weekly intraperitoneal injection of Jo2, an anti-Fas antibody agonist of Fas ligand (22). This antibody was found to be specific to mouse hepatocytes, since rat hepatocytes were shown to be naturally resistant to the Jo2 effect (14,34). Jo2 has been reported to induce transitory fulminant hepatic failure in various mouse models after a single injection (17,22,26), characterized by an elevation of serological alanine transaminase (ALT) for the first 3 days. The survival rates correlated with histological observations of liver necrosis. We and others have found that liver deficiency injury was a dose-dependent effect and was reversible within 10 days (14). The regenerative capacity of the liver was thus retained after Jo2 injection, making its use attractive for studying the efficacy of hepatocyte transplantation. We also found that when Jo2 was administrated on repeated challenges, each Jo2 injection induced an episode of fulminant hepatic failure.

In our recent study, we found an increased liver engraftment of rat hepatocytes into nude mouse livers when transplantation was followed by a weekly Jo2 treatment with a sublethal (mortality inferior to 33%) dose of 250 μg/kg weight, compared to that obtained when transplanted into control mice (14). Genomic analysis of livers of these sublethal Jo2 weekly treated mice revealed a transcriptome profile with upregulation of cellular cycle blocking transcripts (especially an elevated level of gene p21, cyclindependent kinase inhibitor 1, controlling cell cycle G₁ phase arrest), activation of liver injury-inducing interferon (IFN)-γ /signal transducer and activator of transcription 1 (STAT1) pathway, circadian transcript signature of antiproliferative cell status, and minor inflammatory responses. All of these modifications indicated an important cell cycle blockade, following the last Jo2 injection. The overall transcriptome profile suggested that Jo2-treated nude mice might correspond to a model of selective advantage where cell cycle blockade occurred in mouse hepatocytes submitted to weekly Jo2 treatment, while natural resistance to Jo2 of rat hepatocytes allowed them to proliferate.

The first aim of the present study was to assess human hepatocyte engraftment into the Jo2-treated nude mouse model of acute liver failure. For this study, freshly isolated human hepatocytes (FHCs) were transplanted into nude mice subjected to repeated Jo2 injections of 250 μg /kg weight, and genomic analysis of nude mouse hepatic parenchyma was performed.

The second aim of the present study was to evaluate the therapeutic efficacy of hepatocyte transplantation in fulminant hepatitis by using lethal Jo2 doses of 350 μg/kg weight and assessing survival of transplanted and non-transplanted mice.

Materials and Methods

Chemicals and Reagents

All chemical compounds were obtained from Sigma-Aldrich (St. Quentin-Fallavier, France). Culture media, fetal calf serum, and antibiotics were purchased from Invitrogen (Cergy Pontoise, France). Cell culture plates were obtained from Dutscher (Brumath, France).

Animals

Male nude mice 8 to 10 weeks old used for cell transplantation were housed individually, placed in a ventilated cabinet under controlled air pressure and temperature conditions, and under daily cycles of alternating 12-h light/darkness. They had sterile water and sterile standard pelleted rodent diet, ad libidum. Male Sprague–Dawley rats (180–200 g) and mice (CD1) were used for hepatocyte isolation. All animals were purchased from Charles River Laboratories (L'Arbresle, France). All experiments were conducted according to local institution guidelines for the care and the use of laboratory animals.

All operations were performed between 10 am and 12 pm, under general anesthesia, using a sterile surgical technique.

Hepatocyte Isolation

All experimental procedures were performed in compliance with respective French laws and regulations after approval by the National Ethics Committee. Informed consent was obtained from the patients for the use of liver tissue for research purposes. Hepatocytes were isolated by a two-step collagenase method according to Alexandre et al. (1) and Richert et al. (38). Donor characteristics are summarized in Table 1. Briefly, on arrival at the laboratory, the liver was removed from the transportation bag, placed on ice-cold washing buffer [0.8 mM Na₂HPO₄, 0.5 mM ethylene glycol tetraacetic acid (EGTA), 2.7 mM KCl, and 137 mM NaCl, pH 7.4], two to four cannulae (Vasculon 14–20 gauze, vein size dependent, Becton Dickinson, Le Pont de Claix, France) were inserted into the major vessels, and the cut surface of the liver was coated with a collar glue (Super Glue 3, Loctite, Henckel Loctite France, Marne-la-Vallée, France) to avoid leakage of the perfusate. A washing step was initiated by using the prewarmed (37°C) washing buffer without recirculation [20–40 ml/min/cannula (depending on the size of the specimen)] for 10 min at 37°C. This perfusion medium was discarded, and the digestion step was started by recirculation of the digestion buffer at 37°C [0.8 mM Na₂HPO₄, 2.7 mM KCl, and 137 mM NaCl, 0.05% w/v collagenase (Gibco powdered collagenase for hepatocyte isolation; Invitrogen, Cergy Pontoise, France), pH 7.4] for 20–30 min at a flow rate of 20–40 ml/min/cannula (depending on the size of the specimen). After the digestion step, the cell suspension, obtained by smooth mechanic dissociation and filtered through three stainless steel strainers (850, 425, and 106 mm diameter, respectively, Dominique Dutscher, Brumath, France), was centrifuged at 75 × g for 5 min at 37°C. The cell pellet was washed three times with Hank's balanced salt solution (HBSS). Cell yield and viability were estimated by trypan blue dye exclusion and counting the cells using a Malassez hemocytometer (WWR, Strasbourg, France).

Table 1.

Donor Information for Human Hepatocyte Preparations

Donor HH#	Age (Years)	Sex (M/F)	Race	Pathology	Cell Viability (%)
121206	68	F	C	Colorectal adenocarcinoma	92
041005	69	F	C	Colorectal adenocarcinoma	87
060105	49	F	C	Breast adenocarcinoma	90
241204	62	M	C	Colorectal adenocarcinoma	95
241104	43	F	C	Colorectal adenocarcinoma	85
290305	79	M	C	Parathyroid adenoma	89

M, male; F, female; C, caucasian.

MTT Cytotoxicity Test

Hepatocytes from different species (human, mouse, and rat) were seeded in Biocoat 96-well plates at a density of 50,000 cells/well in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal calf serum, containing insulin (4 mg/ml), dexamethasone (1 μM), and antibiotics (gentamicine). After overnight plating, cells were treated for 24 h with increasing concentrations of Jo2 (0, 0.1, 1, 10, 100, 500, 1,000 ng/ml). After 24 h of treatment, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed, according to literature data (5), to assess cell viability.

Liver Injury Induction

The purified hamster anti-mouse Fas monoclonal antibody, Jo2 (PharMingen, Becton Dickinson, France), was used to induce acute liver failure in nude mice, by intraperitoneal injections. Animals received either a repeated 250 μg/kg body weight dose of Jo2 (n = 21) weekly during 21 days (Group 250), or at day 0, a single 250 μg/kg body weight followed at day 7 by a 375 μg/kg body weight dose of Jo2 (n = 21) repeated weekly until day 21 (Group 375). Three animals in each group were kept alive until day 57 (for 8 weeks). A control group of animals was not submitted to Jo2 treatment.

Hepatocyte Transplantation

Intrasplenic hepatocyte transplantation was performed on 8- to 10-week-old male nude mice under anesthesia [by breathing 2 L/min O₂ containing 3% enflurane (Forene^®, Abbott, Rungis, France)] 24 h after the first liver injury induction. After an abdominal midline incision, the spleen was mobilized, and 1 × 10⁶ human hepatocytes suspended in 100 μl HBSS were slowly injected into the spleen parenchyma using a 30-gauge needle. Hemostasis was realized at the point of injection by dabbing with Surgicell^® gauze (Johnson & Johnson, New Brunswick, NJ, USA). Hepatocytes migrate to the liver, and successful injection was approved by a short-term paleness of the liver lobes. The animals were sacrificed 21 days after hepatocyte transplantation, except for three animals per group, for which the experiment kept running for 8 weeks. These three animals were subjected to weekly Jo2 injections and sacrificed on day 57 (Table 2). One part of the liver was snap frozen in liquid nitrogen and stored at −80°C until genomic analysis could be performed, and one part was embedded in optimal cutting temperature (OCT) compound (Tissue-Tek, Elkhart, IN, USA) and snap frozen in isopentane, for cryosection and immunostaining with an anti-human cytokeratin 18 (CK18) antibody (M 7010, DAKO, Les Ulis, France) (see below).

Table 2.

Different Experimental Groups of Nude Mice, Treated or Not by Jo2 (Anti-Fas Antibody) Weekly Injection and Transplanted or Not With Freshly Isolated Human Hepatocytes (FHCs)

		n	Day 0	Day 1	Day 8	Day 15	Day 21	Day 22	Day 57
Group 250	Group Transpl	5		FHCs				Sacrifice
	Group 250Jo2	6	250 μg/kg Jo2	-	250 μg/kg Jo2	250 μg/kg Jo2	250 μg/kg Jo2	Sacrifice
	Group Transpl_250	15	250 μg/kg Jo2	FHCs	375 μg/kg Jo2	375 μg/kg Jo2	375 μg/kg Jo2	Sacrifice of all survivors, except 3	Sacrifice of 3, after 5 weekly 375 μg/kg Jo2
Group 375	Group 375Jo2	11	250 μg/kg Jo2	-	375 μg/kg Jo2	375 μg/kg Jo2	375 μg/kg Jo2	Sacrifice
	Group Transpl_375	10	250 μg/kg Jo2	FHC	375 μg/kg Jo2	375 μg/kg Jo2	375 μg/kg Jo2	Sacrifice of all survivors, except 3	Sacrifice of 3, after 5 weekly 375 μg/kg Jo2

Experimental Groups for Hepatocyte Transplantation (Table 2)

The control group of animals did not undergo liver injury and were transplanted with freshly isolated human hepatocytes (Group Transpl, n = 5).

Two groups underwent liver injury either with weekly 250 μg/kg of Jo2 (Group 250) or with weekly 375 μg/kg of Jo2 (Group 375). They were either submitted or not to transplantation:

Without hepatocyte transplantation (Group 250Jo2, n = 6 and Group 375Jo2, n = 11)

Transplanted with freshly isolated human hepatocytes in nude mouse treated by repeated body weight dose of Jo2 (Group Transpl_250, n = 15)

Transplanted with freshly isolated human hepatocytes in nude mouse treated by repeated 375 μg/kg body weight dose of Jo2 (Group Transpl_375, n = 10)

Seric Parameters

Blood samples were taken each day following Jo2 injection from day 7 to day 22, on anesthetized animals (as above) via the caudal vein. Serum samples were obtained by centrifugation of collected blood 10 min at 3,000 × g. Catalytic activity of ALT (U/L) was determined by means of reflectometry using an automatic Kodak Ektachem 500 analyzer (Vincennes, France).

Gel Electrophoresis and Western Blotting Analysis

Human albumin levels in nude mice serum, in suspension of 10⁶ hepatocytes and in liver samples 22 days after the beginning of the experiment, were estimated qualitatively and semiquantitatively. Proteins (10–50 μg) were separated by 7% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) according to Laemmli (27) and then electrophoretically transferred onto nitrocellulose membrane of 0.22 μm (Schleicher and Schuell, Dassel, Germany) for Western blot analysis (4). The blots were incubated overnight at 4°C with the primary antibody: an affinity-purified human albumin antibody produced in goat (1:8,000, Bethyl Laboratories, Inc., Interchim, France). Detection of the primary antibody was performed using a commercial Vectastain Elite ABC Kit (Vector Laboratories, Biovalley, France) as described by the manufacturer. Positive signals were detected by the enhanced chemiluminescence method (Amersham Life Science, Inc., Velizy-Villacoublay, France). Relative amounts of albumin were determined by densitometry using a scanner and quantified using a computer program (Quantity One Basic 1-D Analysis Software, Biorad Laboratories, Marnes-la-Coquette, France).

Liver Ki-67 Immunostaining

Cryofrozen liver sections (4 μm) were fixed in cold methanol for 10 min and rinsed in phosphate-buffered saline (PBS) for 3 min before being immersed in a 10-mM citrate sodium bath (pH 6) exposed to microwaving during 10 min. After 1 h at room temperature, slides were rinsed in PBS (5 min, three times), specific endogenous peroxidase activity was inhibited by H₂O₂ (0.5% in methanol) for 30 min, followed by another rinsing step in PBS (5 min, three times) and then incubated overnight at 4°C with Ab833 rabbit polyclonal antibody to human Ki-67 antigen (Abcam, Interchim, France) diluted (1:50) in PBS. After rinsing in PBS (5 min, three times), a 1:200 dilution in PBS of biotinylated goat anti-rabbit IgG (H+L) antibody (Jackson ImmunoResearch Laboratories, Interchim, France) was added for 1 h. A commercial kit (Vectastain® Elite® ABC kit; Vector Laboratories) was used for amplification of the signal before 0.3 mg/ml diaminobenzidine (supplemented with 0.03% H₂O₂) was added to each slide (10 min, in the dark). After two successive sterile water washes (3 min each), sections were dried for 1 h before being mounted in Eukitt® medium (CML, Nemours, France). Percentage of Ki-67-positive cell staining was determined between the different samples. Negative control was mouse IgG (X 0931; Dako; 1:50).

Ki-67 immunostaining was performed in all animals of Group Transpl_250 and Group Transpl_375, on the liver removed at the time of autopsy, and on animals that died during the experiment, if the death was noticed rapidly after its occurrence.

Liver CK18 Immunostaining

This was performed the same as for Ki-67 except as outlined below.

Antigen retrieval was by microwaving for 20 min in 10 mmol/L Tris buffer, 1 mmol/L EDTA, pH 9. The slides were incubated 30 min at room temperature with monoclonal mouse anti-human cytokeratin 18 antibody (Dako) diluted (1:50) in PBS. After rinsing in PBS (5 min, three times), a 1:200 dilution in PBS of biotinylated goat antimouse IgG (H+L) antibody (Jackson ImmunoResearch Laboratories, Interchim, France) was added for 30 min at room temperature. Visualization was performed using the Vectastain^® Elite^® ABC kit and diaminobenzidine as described above before the sections were dried for 1 h before being mounted in Eukitt^® medium.

Hepatocyte Engraftment

In order to evaluate the number of engrafted cells, albumin content of transplanted livers, as determined by Western blotting, was divided by the albumin content of 10⁶ hepatocytes of the given batch of transplanted hepatocytes.

Statistics

Results were expressed as mean ± SEM. Differences among means were assessed using computer-aided unpaired t test (Statview^® 4.5 software, Abacus Concept, Berkeley, CA, USA). When multiple comparisons were done (comparing different groups to a control group), Bonferroni correction was used. Survival curves were analyzed using log rank test. Values of p < 0.05 were considered significant.

Genomic Analysis

RNA Preparation

One part (left lobe) of mouse liver samples was frozen in liquid nitrogen immediately after removal and was used for RNA preparation and DNA microarray experiments. Total RNA from liver tissue samples was extracted after homogenization with a rotor stator homogenizer (Ultra Turrax; IKA, Staufen, Germany) with TRIzol Reagent (Invitrogen) and purified using RNeasy Mini Kit (Qiagen, Courtaboeuf, France) according to the manufacturers' instructions. Total RNA was quantified by absorbance at 260 nm (A260 nm), and purity was checked by the A260 nm/A280 nm ratio (Gene Quant pro photometer, Amersham). The RNA samples were stored at −80°C before analysis.

DNA Microarray Experiments

DNA microarray experiments were conducted as recommended by the manufacturer of the GeneChip system (Affymetrix, Santa Clara, CA, http://www.affymetrix.com). Samples were hybridized to MOE430A GeneChip arrays. The resultant image files (.dat files) were processed using the Microarray Analysis Suite 5 (MAS5; Affymetrix) software package from which numerical signal intensity (Signal) data and categorical expression level measurements (Absolute Call) were obtained. All data were quality checked and were transferred to other software packages for analysis. The mouse genome-specific MOE430A GeneChip expression probe arrays containing more than 45,000 probe sets interrogating more than 39,000 transcripts included wellsubstantiated genes and also expressed sequence tag (EST) clusters. One GeneChip was used per animal.

Statistical Data Analysis.

Data Pretreatment

The MAS 5 processed raw expression intensities were subjected to a filtering. Only probe sets with a median intensity of larger than 50 and 3 (or more) “present” or “marginal” calls in at least one of the treatment groups were used in the subsequent statistical analyses. A total of 18,156 probe sets satisfied the two filter criteria. The intensity data were then log2-transformed with an offset of 1.

Statistical Analysis

A one-way analysis of variance (ANOVA) using group as the independent variable was fit to the filtered and transformed data of all samples. The transplanted Transpl_250 and Transpl_375 groups were compared to the transplanted control group. These comparisons were made using linear contrasts within the framework of the ANOVA models (2). The calculated fold changes are based upon geometric means. The principal component analysis (PCA) and ANOVA calculations were performed with Partek Pro 6.2 (Partek, Inc., St. Louis, MO, USA). The Affymetrix probe sets were annotated using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 2.0 (8). Expressed sequence tags (ESTs) were not considered for biological interpretation.

Results

Mouse Selectivity of the Cytotoxicity of Anti-Fas Jo2 Antibody

Human hepatocytes were cultured overnight and treated with increasing concentrations of Jo2 (0, 0.1, 1, 10, 100, 500, 1,000 ng/ml). Assays with rat and mouse hepatocytes were performed in parallel. After 24 h in culture, a MTT test was performed, and viability of cells treated with increasing concentrations of Jo2 was expressed as percentage of the control value (0 ng/ml).

As shown in Figure 1, no cytotoxic activity of Jo2 against human or rat hepatocytes was found up to 1,000 ng/ml, while the sensitivity of mouse hepatocytes to more than 1 ng/ml was confirmed.

Figure 1.

Cytotoxicity of Jo2 at increasing concentrations, on hepatocyte cultures from different species. Viability was assessed by MTT assay; 24-h incubation with Jo2.

Induction of Liver Injury Following Jo2 Administration to Nude Mice

For all groups of nude mice, at each time point during the experiment, ALT levels increased significantly (p < 0.05, compared to nontreated control group) 24 h after 250 μg/kg or 375 μg/kg Jo2 treatment (Fig. 2), confirming that liver injury was induced.

Figure 2.

Alanine transaminase (ALT) content in the serum of nude mice. ALT content in the serum of nude mice after transplantation with human freshly isolated hepatocytes (FHCs), and treated without (Group Transpl) or with antibody anti-Fas (Jo2) at a weekly dose of 250 μg/kg (Group Transpl_250) or at a weekly dose of 375 μg/kg (Group Transpl_375). Results are expressed in UI/L as the mean ± SEM in mice serum. Stars indicate a significant increase compared to the control Group Transpl. Arrows indicate each Jo2 injection.

Engraftment Rate of Human Hepatocytes and Levels of Human Albumin in the Serum of Transplanted Nude Mice

Due to the important interindividual fluctuation within each experimental group, all individual results of hepatocyte engraftment calculations and serum human albumin are shown and summarized in Table 3.

Table 3.

Individual Characteristic of Human Hepatocyte Transplantation Results: Hepatocyte Viability Before Transplantation (%), Number of Engrafted Hepatocytes at Autopsy, Human Albumin in Nude Mouse Serum (ng/ml) at Autopsy

Group	Day of Autopsy	Cell Viability Before Transplantation (%)	Number of Engrafted FHCs in Total Liver	Human Albumin in Nude Mouse Serum at Day of Autopsy (ng/ml)
Transpl_250	22	77	5	Nd
	22	77	0	0.83
	22	74	6,000	1.04
	22	74	1,594	2.33
	22	86	35	0.48
	22	86	0	1.34
	57	86	34	Nd
	57	74	1,490	0
	57	74	2,232	2.13
Transpl_375	22	56	2,776	4.64
	22	56	67	10.48
	22	56	736	0.42
	22	56	19	1.55
	22	56	41	1.91
	22	56	0	1.43
	57	56	0	1.11
	57	56	0	4.19
Transpl	22	72	1,648	0.18
	22	72	399	1.7
	22	72	0	1.51
	22	72	0	0.3
	22	72	0	1.33

FHCs, fresh human hepatocytes; Nd, not determined.

Human albumin was undetectable in sera from nontransplanted nude mice (receiving Jo2 repeat treatment). In mice transplanted with human hepatocytes, human serum albumin could be measured at low levels at day 22, in all groups: group not treated with Jo2 (1.004 ± 0.293 ng/ml serum), group receiving 250 μg/kg of Jo2 (1.719 ± 0.683 ng/ml serum), and group receiving 375 μg/kg of Jo2 (3.569 ± 1.302 ng/ml serum).

Results of liver repopulation are listed in Table 3. The human hepatocyte engraftment rate was calculated by measuring the percentage of human albumin in transplanted mouse livers. In the three groups, half of the animals showed strictly no liver engraftment of human hepatocytes. In the remaining animals, the human hepatocyte engraftment remained very low, whatever the dose of Jo2. Even if taking the best engraftment rate of human hepatocytes (6,000 cells by liver), and hypothesizing that a nude mouse liver contains approximately 10⁸ hepatocytes (19), it would correspond to 0.006% of repopulation, which can be considered as a failure of human hepatocyte engraftment into the recipient liver. These results were confirmed by immunostaining with an anti-human CK18 antibody and evaluation of engraftment by counting the number of positive cells within randomly chosen microscope fields (data not shown).

There was no evidence for ectopic engraftment since no human hepatocyte presence could be found in the spleen, heart, bowel, or lung tissue (data not shown).

Taken together, the results observed with human hepatocytes were opposite to those previously reported with rat hepatocytes (42). Indeed, engraftment of transplanted rat hepatocytes was observed in all animals, and the repopulation rate was estimated at 2.4%, which was sevenfold higher than that of rat hepatocyte repopulation in the nude mouse not treated with Jo2 (42).

Effect of Transplantation on the Survival Rate of Jo2-Treated Nude Mice

We first confirmed that repeated 250 μg/kg Jo2 injections was a sublethal model, with a survival rate of 67% at 3 weeks, mortality occurring during the 24 h following each Jo2 injection, as found in our previous experiments (42). When nude mice were challenged with higher weekly doses of 375 μg/kg Jo2 from day 7 until day 21, survival rate decreased to 33% at 3 weeks. As we aimed at comparing the benefits of hepatocyte transplantation on the survival rate of Jo2-treated nude mice, the survival rate at day 1 (i.e., the day of hepatocyte transplantation) was considered 100% (Fig. 3).

Figure 3.

Nude mouse survival after treatments. Survival (% of day 1) of nude mice treated with antibody anti-Fas (Jo2) at a weekly dose of 250 μg/kg (Group 250Jo2 and Group Transpl_250) or at a weekly dose of 375 μg/kg (Group 375Jo2 and Group Transpl_375). Arrows indicate each Jo2 injection.

In the group submitted to 250 μg/kg Jo2 doses, the survival rate after transplantation of human hepatocytes was 64.3%, equivalent to the nontransplanted corresponding controls (Fig. 3), also confirming our previous data (42).

In the lethal model, the survival rate increased to 80% when animals were transplanted with human hepatocytes (Fig. 3), and this gain of survival was found to be significant (p = 0.046).

Genomic Analysis of Transplanted Mice

Genomic analysis was performed in mice submitted to transplantation only (Transpl_group) and in mice submitted to subsequent repeated 250 μg/kg Jo2 treatments (Transpl_250 group) or to repeated 375 μg/kg Jo2 treatments (Transpl_375 group).

When comparing genomic analysis results from Transpl_250 group and Transpl_group, 41 different genes were upregulated, and 16 genes were downregulated (Table 4).

Table 4.

Genes Up- and Downregulated in Group of Nude Mouse Treated by Weekly 250 μg/kg Jo2 Dose and Transplanted With Freshly Isolated Human Hepatocytes (Transpl_250 group) Versus Control Transplanted Group of Nude Mice (Transpl_group)

Probe Set ID	p Value	G-Mean Ratio	G-Fold Change		Dysregulated Genes in Transpl_250 Versus Transpl
Upregulated Genes
1438211_s_at	0.001	27.63	27.63	Dbp	D site albumin promoter-binding protein
1426464_at	0.000	20.72	20.72	Nr1d1	Nuclear receptor subfamily 1, group D, member 1
1423100_at	0.001	20.12	20.12	Fos	FBJ osteosarcoma oncogene
1426037_a_at	0.008	17.82	17.82	Rgs16	Regulator of G-protein signaling 16
1417065_at	0.001	15.98	15.98	Egr1	Early growth response 1
1449326_x_at	0.003	10.82	10.82	Saa2	Serum amyloid A 2
1457823_at	0.001	10.39	10.39	Cyr61	Cysteine-rich protein 61
1457644_s_at	0.000	9.33	9.33	Cxcl1	Chemokine (C-X-C motif) ligand 1
1422557_s_at	0.001	9.02	9.02	Mt1	Metallothionein 1
1441910_x_at	0.001	7.69	7.69	Ccne1	Cyclin E1
1419075_s_at	0.002	7.10	7.10	Saa1	Serum amyloid A 1
1459253_at	0.003	6.83	6.83	Arrdc3	Arrestin domain containing 3
1428942_at	0.004	6.64	6.64	Mt2	Metallothionein 2
1416958_at	0.002	6.44	6.44	Nr1d2	Nuclear receptor subfamily 1, group D, member 2
1415899_at	0.000	5.93	5.93	Junb	Jun-B oncogene
1438033_at	0.001	5.82	5.82	Tef	Thyrotroph embryonic factor
1439301_at	0.007	5.55	5.55	Rad51l1	RAD51-like 1 (S. cerevisiae)
1444166_at	0.002	5.47	5.47	Thrsp	Thyroid hormone-responsive SPOT14 homolog (Rattus)
1458176_at	0.002	5.31	5.31	Per3	Period homolog 3 (Drosophila)
1439566_at	0.002	5.22	5.22	Gprin3	GPRIN family member 3
1453851_a_at	0.002	4.97	4.97	Gadd45g	Growth arrest and DNA-damage-inducible 45 g
1426597_s_at	0.001	4.81	4.81	C79267	Expressed sequence C79267
1416801_at	0.006	4.74	4.74	Trpm7	Transient receptor potential cation channel, subfamily M, member 7
1437554_at	0.010	4.72	4.72	Plec1	Plectin 1
1456225_x_at	0.003	4.61	4.61	Trib3	Tribbles homolog 3 (Drosophila)
1416250_at	0.004	4.46	4.46	Btg2	B-Cell translocation gene 2, anti-proliferative
1456488_at	0.004	4.31	4.31	Wdr33	WD repeat domain 33
1444518_at	0.003	4.17	4.17	Acox1	Acyl-coenzyme A oxidase 1, palmitoyl
1448147_at	0.001	4.13	4.13	Tnfrsf19	Tumor necrosis factor receptor superfamily, member 19
1435135_at	0.000	4.03	4.03	Aadacl1	Arylacetamide deacetylase-like 1
1426432_a_at	0.000	3.97	3.97	Slc4a4	Solute carrier family 4 (anion exchanger), member 4
1438329_at	0.001	3.77	3.77	Tlr12	Toll-like receptor 12
1446230_at	0.000	3.71	3.71	Gm944	Gene model 944, (NCBI)
1459984_at	0.010	3.65	3.65	Mia3	melanoma inhibitory activity 3
1442331_at	0.009	3.46	3.46	Alas1	Aminolevulinic acid synthase 1
1452519_a_at	0.001	3.30	3.30	Zfp36	Zinc finger protein 36
1447164_at	0.001	3.17	3.17	Rlf	Rearranged L-myc fusion sequence
1453596_at	0.002	3.16	3.16	Id2	Inhibitor of DNA binding 2
1424402_at	0.006	3.13	3.13	Rufy3	RUN and FYVE domain containing 3
1434350_at	0.001	3.09	3.09	Axud1	AXIN1 upregulated 1
1451382_at	0.003	3.01	3.01	Chac1	ChaC, cation transport regulator-like 1 (E. coli)
Downregulated Genes
1425099_a_at	0.003	0.14	-7.00	Arntl	Aryl hydrocarbon receptor nuclear translocator-like
1420722_at	0.000	0.15	-6.61	Elovl3	Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3
1452318_a_at	0.001	0.16	-6.08	Hspa1b	Heat shock protein 1B
1439797_at	0.000	0.19	-5.21	Ppard	Peroxisome proliferator activator receptor d
1452388_at	0.000	0.20	-4.91	Hspa1a	Heat shock protein 1A
1425792_a_at	0.000	0.25	-3.95	Rorc	RAR-related orphan receptor g
142481 1_at	0.000	0.27	-3.64	Cml5	Camello-like 5
1436200_at	0.000	0.28	-3.60	Lonrf3	LON peptidase N-terminal domain and ring finger 3
1449948_at	0.004	0.29	-3.50	Ero1lb	ERO1-like β (S. cerevisiae)
1425964_x_at	0.001	0.30	-3.35	Hspb1	Heat shock protein 1
1436590_at	0.000	0.31	-3.26	Ppp1r3b	Protein phosphatase 1, regulatory (inhibitor) subunit 3B
1425868_at	0.004	0.31	-3.25	Hist2h2bb	Histone cluster 2, H2bb
1423566_a_at	0.000	0.31	-3.24	Hsp110	Heat shock protein 110
1419874_x_at	0.000	0.32	-3.17	Zbtb16	Zinc finger and BTB domain containing 16
1452754_at	0.002	0.32	-3.15	Creld2	Cysteine-rich with EGF-like domains 2
1426519_at	0.000	0.32	-3.11	P4ha1	Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), a 1 polypeptide
1419663_at	0.007	0.33	-3.00	Ogn	Osteoglycin

Among the upregulated genes, we could isolate genes involved in cell proliferation such as Fos, a proto-oncogene, Egr1 (early growth response 1), cyclin 1, and methallothioneins. These genes are known to appear early after liver injury, and they signal a liver regeneration response. Some inflammation marker genes were upregulated such as serum amyloid (Saa) 1 and 2. A few genes that can be seen with macrophage activation were also found such as chemokines or Toll-like receptor (Tlr).

Interestingly, the most upregulated genes were clock genes: Dbp (D-site of albumin promoter) (27-fold) and Nr1D1 (nuclear receptor subfamily 1, group D, number 1). Other circadian cycle regulator genes were also upregulated like Nr1D2 (nuclear receptor subfamily 1, group D, number 2) also called Rev-Erb β, Per3 (Period 3), and Tef (thyrotrophic embryonic factor). This upregulation of circadian genes was interpreted as linked with increased cellular proliferative status.

Among the downregulated genes were some heat shock proteins and Arntl (aryl hydrocarbon receptor nuclear translocator-like), also called Bmal1 (brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1), another circadian gene.

Taken altogether, the results were different from those obtained when comparing rat hepatocyte transplantation into the repeated 250 μg/kg Jo2 injections nude mouse model versus rat hepatocyte transplantation alone (42). While all the circadian genes were downregulated in the livers of nude mice transplanted with rat hepatocytes, they were strongly upregulated in livers of nude mice transplanted with human hepatocytes (Fig. 4).

Figure 4.

Comparative mRNA expression of circadian-related transcripts in nude mice transplanted in rat hepatocytes (white) or fresh human hepatocytes (black) after weekly injection of 250 μg/kg Jo2. mRNA measured by Affymetrix mouse genome-specific MOE430A GeneChip array.

In our previous rat hepatocyte transplantation study, we found a “signature” for blockade of cell proliferation (with P21, a cell cycle arrest gene, as the most upregulated gene associated with a downregulation of circadian genes), of interferon γ pathway activation, and of moderate inflammation, and we could not isolate early genes. In the present study, where we compared nude mice receiving a weekly 250 μg/kg Jo2 dose after transplantation with human hepatocytes (Transpl_250 group) with human hepatocyte transplantation alone (Transpl_group), we found an inverted “signature” of stimulation of liver regeneration: lack of P21 upregulation, upregulation of early response genes, and upregulation of circadian genes.

Genomic analysis comparing human hepatocyte transplantation in the 375 μg/kg Jo2 model (Transpl_375 group) to human hepatocyte transplantation alone (Transpl_group) revealed 26 upregulated genes and six downregulated genes (Table 5).

Table 5.

Genes Up- and Downregulated in Group of Nude Mouse Treated by Weekly 375 μg/kg Jo2 Dose and Transplanted With FHCs (Transpl_375 group) Versus Control Transplanted Group of Nude Mice (Transpl group)

Probe Set ID	p Value	G-Mean Ratio	G-Fold Change		Dysregulated Genes in Transpl_375 Versus Transpl
Upregulated genes
1451612_at	0.002	18.36	18.36	Mt1	Metallothionein 1
1449326_x_at	0.001	16.15	16.15	Saa2	Serum amyloid A 2
1427747_a_at	0.005	14.76	14.76	Lcn2	Lipocalin 2
1428942_at	0.001	9.82	9.82	Mt2	Metallothionein 2
1419075_s_at	0.000	9.80	9.80	Saa1	Serum amyloid A 1
1421228_at	0.005	7.32	7.32	Ccl7	Chemokine (C-C motif) ligand 7
1417065_at	0.009	7.12	7.12	Egr1	Early growth response 1
1418918_at	0.004	6.58	6.58	Igfbp1	Insulin-like growth factor-binding protein 1
1457644_s_at	0.001	5.71	5.71	Cxcl1	Chemokine (C-X-C motif) ligand 1
1436058_at	0.007	5.01	5.01	Rsad2	Radical S-adenosyl methionine domain containing 2
1417256_at	0.008	5.00	5.00	Mmp13	Matrix metallopeptidase 13
1441910_x_at	0.007	4.42	4.42	Ccne1	Cyclin E1
1419394_s_at	0.002	4.27	4.27	S100a8	S100 calcium binding protein A8 (calgranulin A)
1424923_at	0.009	4.13	4.13	Serpina3g	Serine (or cysteine) peptidase inhibitor, clade A, member 3G
1419004_s_at	0.005	4.01	4.01	Bcl2a1a	B-Cell leukemia/lymphoma 2-related protein A1a
1449846_at	0.005	3.62	3.62	Ear2	Eosinophil-associated, ribonuclease A family, member 2
1417849_at	0.003	3.62	3.62	Zfp704	Zinc finger protein 704
1448756_at	0.005	3.47	3.47	S100a9	S100 calcium-binding protein A9 (calgranulin B)
1453345_at	0.010	3.47	3.47	Npal1	NIPA-like domain containing 1
1433699_at	0.006	3.33	3.33	Tnfaip3	Tumor necrosis factor, α-induced protein 3
1425156_at	0.009	3.32	3.32	Gbp6	Guanylate-binding protein 6
1442798_x_at	0.004	3.28	3.28	Hk3	Hexokinase 3
1455269_a_at	0.003	3.25	3.25	Coro1a	Coronin, actin-binding protein 1A
1417185_at	0.001	3.12	3.12	Ly6a	Lymphocyte antigen 6 complex, locus A
1459159_a_at	0.009	3.05	3.05	Ccdc6	Coiled-coil domain containing 6
1423606_at	0.009	3.03	3.03	Postn	Periostin, osteoblast-specific factor
Downregulated genes
1418857_at	0.006	0.20	-4.98	Slc13a2	Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2
1447700_x_at	0.006	0.23	-4.43	Ss18l1	Synovial sarcoma translocation gene on chromosome 18-like 1
1425631_at	0.001	0.23	-4.31	Ppp1r3c	Protein phosphatase 1, regulatory (inhibitor) subunit 3C
1420722_at	0.002	0.24	-4.19	Elovl3	Elongation of very long c hain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3
1429285_at	0.003	0.28	-3.63	Serpina9	Serine (or cysteine) peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 9
1453023_at	0.007	0.33	-3.04	Ankhd1	Ankyrin repeat and KH domain containing 1

The upregulated genes were similar to those found when comparing Transpl_250 group to Transpl_group: they belong to the family of regulators of cell proliferation, such as metallothionein, Egr, cyclin E1, and to inflammation genes such as Saa1 and Saa2, or matrix metalloprotease (Mmp). Thus, the signature of Transpl_375 group very closely resembled that of Transpl_250 group. The major difference was the absence of neither up- nor downregulation of circadian genes. The PCA of the three groups showed two distinct, clearly separated groups: Transpl_375 and Transpl, while Transpl_250 and Transpl_375 were close (Fig. 5).

Figure 5.

Principal component analysis (PCA) of genomic analysis of nude mice after treatment. PCA of genomic analysis of the three groups of nude mice after transplantation with human freshly isolated hepatocytes treated without (“A” Group Transpl) or with antibody anti-Fas (Jo2) at a weekly dose of 250 μg/kg (“B” Group Transpl_250) or at a weekly dose of 375 μg/kg (“C” Group Transpl_375).

Discussion

Nude Mouse Model of Repeated Lethal Liver Deficiency

In the present experiment, repeated liver injury was induced in nude mice by a weekly challenge of Jo2 at 250 or 375 μg/kg for 3 to 8 weeks. The 67% survival observed at 250 μg/kg confirmed our previous report (42) and was therefore considered as a sublethal dose. Survival rate decreased to 36%, when repeated liver injury was induced by 375 μg/kg Jo2, confirming lethality. In both groups, mortality was observed each 24 h following Jo2 injection.

Failure of Human Hepatocyte Liver Engraftment in Repeatedly Jo2-Treated Nude Mice

To assess human hepatocyte engraftment, we used two criteria: serum human albumin rate and human albumin in nude mice liver. In both groups, serum human albumin concentrations were variable and did not correlate with liver repopulation. This was previously reported for the uPA (urokinase plasminogen activator) transgenic mouse model transplanted with human hepatocytes, in which human hepatocyte engraftment raised a rate up to 90%, while the proportion of murine/human albumin in the blood sample did not exceed 10% (29), suggesting that functional human hepatocyte engraftment can occur without improvement of serum albumin. Moreover, the smaller the engraftment, the more difficult it is to detect the human serum albumin (6,31). Thus, human serum albumin might not be the good criteria for evaluation of cell engraftment.

Regarding liver repopulation by human hepatocytes, we obtained a rate of human hepatocyte engraftment that did not exceed 6,000 cells per liver, a much lower rate than what could be expected from our rat hepatocyte engraftment results of 2.4% (42). This corresponds to a repopulation rate evaluated at 0.006% and could be interpreted as a failure of engraftment of human hepatocytes in Jo2 untreated, 250Jo2, and 375Jo2 groups. Such a failure in liver repopulation could be expected in animals not receiving Jo2 since no selective advantage occurred. For groups submitted to Jo2 treatment, the lack of liver repopulation contrasts with the results described when either murine syngenic or human immortalized hepatocytes were transplanted.

In the literature, the engraftment rate of hepatocytes into recipient livers of animals submitted to repeated Jo2 administration in a murine syngenic model is very variable: Fujino et al. (12) obtained a mean repopulation rate of 7%, whereas Gilgenkrantz's group obtained between 4% and 30% of repopulation, depending on the model used (32,33). A 4% mean implantation rate (range from 2% to 6%) was reported in a model of CBA mouse submitted to repeated Jo2 challenges, after transplantation of transduced B-cell CLL/lymphoma 2 (BCl2) overexpressing rat hepatocytes (32), while a mean 30% of repopulation (ranging from 1% to 30%) was obtained in an apoliprotein E knockout (ApoE^-/-) mouse submitted to repeated Jo2 challenges after transplantation of transduced BCl2 overexpressing hepatocytes that expressed constitutively ApoE (33). These engraftment rates were, however, low compared to those obtained in urinary protein-urokinasetype plasminogen activator (uPA) transgenic mice, retrorsine models, or fumaryl-acetoacetate hydrolase (FAH) null mouse, where repopulation by mouse hepatocytes raised up to 80–85% (3,16,25,43).

By using the xenogenic human–rodent transplantation model severe combined immunodeficient (SCID) beige mouse with liver injury caused by repeated Jo2 challenge of 0.2 mg/kg in which HepaRG, an immortalized female human hepatocyte cell line, was transplanted, there was a lack of engraftment in 18 over 29 mice despite the multiplication potential of immortalized cells. Nevertheless, engrafted mice survived, whereas the others died within a few days (21).

Our model of rodent xenogenic transplantation into livers submitted to repeated injury by anti-Fas showed a repopulation of nude mouse liver by rat hepatocytes of 2.4%. Thus, our model was less efficient in developing the appropriate stimuli for rat hepatocyte implantation than for syngenic mouse hepatocyte implantation (32,33), even if genomic analysis showed that it corresponded to a model of selective advantage when transplanting rodent (rat) cells into nude mouse hosts (42). The partially efficient model for rat hepatocyte implantation was poorly supportive for human hepatocyte implantation.

Literature reported difficulties to get implantation of human hepatocyte into mouse models, even in transgenic model uPA mouse or FAH null mouse, where selective advantage climate was the strongest. Dandri et al. described a 70% success rate of the transplanted mice in a model of transplantation of human hepatocytes into uPA/RAG2 mouse liver, with an all-or-none response for human hepatocyte engraftment (7). It is noteworthy that in one third of their animals, however, human hepatocytes did not engraft at all. They correlated this 30% failure result with the time of warm ischemia (more than 90 min) and with the viability of the transplanted cells (less than 80%). These results were confirmed in a model of the uPA/SCID mouse where engraftment was successful in a median of 22% (0–87%) of animals, linked with donor age and warm ischemia (24). In our study, viability of suspended hepatocytes was not a criterion for better results in liver repopulation.

To our knowledge, only a few literature reports have described human hepatocyte transplantation into a nude mouse model. Results of human hepatoblasts (and not mature hepatocytes) transplanted into nude mice after 50% partial hepatectomy gave a liver repopulation from 0.05% to 1% after 6 weeks. However, older hepatoblasts, obtained in the last part of pregnancy (later than 20–24 weeks of gestation), that is, mature cells close to hepatocytes, were not able to repopulate this nude mouse liver (29). When human hepatocytes were transplanted into SCID mice, affected by uPA^-/- knockout, a well-known model of selective advantage, repopulation of human hepatocytes varied from 10% to 90% (7), altogether less than those obtained in syngenic models or murine–murine transplantation models (20). On the other hand, immune mechanisms, even in immunosuppressed mice could act as a brake for xenotransplantation (23).

Meuleman et al. (31) underlined the ability of transplanted human hepatocytes to develop gap junctions with murine host cells, leading to new biliary canalicules. However, these engrafted human hepatocytes presented abnormal glycogenic accumulation that could be due to inappropriate recognition of murine signals.

Thus, one could assume that transplanted human hepatocytes did not receive adapted signals from the mouse liver to engraft and survive as well as in human environment.

Increased Survival Rate of Nude Mice Transplanted with Human Hepatocytes and Subsequently Challenged with Repeated Lethal Doses of Jo2

The 36% mortality rate induced by repeated 375 μg/kg Jo2 treatment could be partially corrected by human hepatocyte transplantation in the lethal model, with a survival rate of 80% in transplanted mice. Thus, human hepatocytes seemed to be able to protect nude mice from liver deficiency, not only for a few days, but even for long term (up to 57 days). This improvement of survival with human hepatocyte transplantation was observed despite a failure of human hepatocyte engraftment.

The increased survival of mice could be due either to hepatocyte action itself or to the transitory presence of fragments of hepatic cells or of growth factors delivered by hepatocytes. However, it has been noted that after liver injury, mortality cannot be corrected by dead hepatocyte transplantation, contrary to living cell transplantation (45). A recent study showed that human albumin released by nonviable human hepatocytes is not detectable in mouse serum 8 days after transplantation (39). In the present study, human albumin was detectable in the serum of transplanted mice at day 22 or day 57, suggesting that if survival improvement was somehow linked to the presence of hepatocytes, it was due to living cells and not dead hepatocytes.

Genomic expression of nude mouse livers strongly differed when rat or human hepatocytes were transplanted. When human cells were transplanted, cell cycle blockage was not seen, and P21 gene expression, which was the most upregulated gene after rat hepatocyte transplantation, was not modified. Many early genes of proliferation were upregulated in mice transplanted with human hepatocytes, whereas none of them was identified when rat hepatocytes were transplanted (42). Moreover, an inverted (up–down) regulation of circadian genes was observed. The circadian genes are known to be involved in the timing of the regenerating mouse livers (30,35,40). The expression of cell cycle-related genes being under control of a circadian clock induces the key regulators of mitosis directly and unidirectionally in proliferating cells. These clock genes can modulate carcinogenesis in liver (10,28). The strong upregulation of circadian rhythm key regulators Per3, their regulator Nr1d2 (alias Rev-erbβ), and their immediate downstream targets (Dbp and Tef) would indicate a high proliferative status of cells in mouse livers. This could be correlated with the absence of P21 (15). When rat hepatocytes were transplanted, we obtained a signature of mouse cell cycle blockage, whereas when human hepatocytes were transplanted, we obtained a signature of a stimulation of proliferation. Taken together, the genomic results could explain the absence of engraftment–-no more selective advantage—cumulated with this paradoxical increased survival rate—stimulation of host cell proliferation— observed in Jo2-treated nude mice transplanted with human hepatocytes. Results of Ki-67 immunostaining show in the two Jo2-transplanted groups a much higher percentage of Ki-67-positive cells in surviving animals compared to those that died during the time course of the experiment (Table 6). This finding correlates with the results of genomic analysis showing regeneration of recipient liver and also with the increased survival rate. Human hepatocytes, by their presence, act as if they could modify the nude mouse cellular environment and trigger cell proliferation.

Table 6.

Percentage of Ki-67-Positive Liver Cells in Group of Nude Mouse Transplanted With Freshly Isolated Human Hepatocytes and Treated by Weekly 250 μg/kg Jo2 Dose (Transpl_250 group) or 375 μg/kg Jo2 Dose (Transpl_375 group)

Group	Sacrifice/Death	Day of Death	Ki-67 (%)
Group	Death	1	30
Transpl_250		2	20
		2	<1
		8	5
		15	10
		15	1
		57	10
	Sacrifice	22	60
		22	50
		22	50
		22	70
		22	40
		22	50
		57	40
		57	50
Group	Death	9	Nd
Transpl_375		16	10
	Sacrifice	22	50
		22	40
		22	50
		22	30
		22	60
		22	40
		57	40
		57	50

We isolated “survivor” animals, but killed for the necessity of the experiment (“sacrifice”), from those that died because of hepatotoxicity of Jo2, during the experiment (“death”).

Literature indicates that cell chronology is species dependent, autonomous, and is not modified by the host nor by the donor cells in a xenogeneic rodent model of transplantation (44).

It could be possible that the differences in chronology of human and murine hepatocyte (6,13) would require a permanent murine signal, as in transgenic uPA or FAH mouse models, to become in-phase for both species and trigger better liver repopulation. It is thus of most importance to assess the outcome of more frequent Jo2 administrations, that is, to shorten the time interval between two challenges where there may be a lack of signal for hepatocyte division and to sustain liver regeneration in recipient livers.

Conclusion

Human hepatocyte transplantation into a nude mouse model of repeated liver injury by Jo2 treatment was a failure in terms of engraftment into recipient liver parenchyma. Genomic analysis showed that the presence of human hepatocytes in nude mouse liver parenchyma modified the changes induced by Jo2 treatment with upregulation of cell proliferation, disappearance of cell cycle blockage, and reversion of circadian antiproliferative status genes. These modifications of the Jo2-induced changes following human hepatocyte transplantation could, at least partly, underline the improved survival rate of nude mice from the group treated with lethal Jo2 when submitted to human hepatocyte transplantation.

Footnotes

Acknowledgments

The authors declare no conflicts of interest.

References

Alexandre

; Cahn

; Abadie-Viollon

; Meyer

; Heyd

; Mantion

; Cinqualbre

; David

; Jaeck

; Richert

Influence of pre-, intra- and post-operative parameters of donor liver on the outcome of isolated human hepatocytes. Cell Tissue Bank. 3(4): 223–233; 2002.

Armitage

; Berry

; Matthews

Statistical methods in medical research. Oxford, England: Blackwell Science; 2002.

Braun

K. M.

; Sandgren

E. P.

Liver disease and compensatory growth: Unexpected lessons from genetically altered mice. Int. J. Dev. Biol. 42(7): 935–942; 1998.

Burnette

W. N.

“Western blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 112(2): 195–203; 1981.

Carmichael

; DeGraff

W. G.

; Gazdar

A. F.

; Minna

J. D.

; Mitchell

J. B.

Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 47(4): 936–942; 1987.

Cho

J. J.

; Joseph

; Sappal

B. S.

; Giri

R. K.

; Wang

; Ludlow

J. W.

; Furth

M. E.

; Susick

; Gupta

Analysis of the functional integrity of cryopreserved human liver cells including xenografting in immunodeficient mice to address suitability for clinical applications. Liver Int. 24(4): 361–370; 2004.

Dandri

; Burda

M. R.

; Torok

; Pollok

J. M.

; Iwanska

; Sommer

; Rogiers

; Rogler

C. E.

; Gupta

; Will

; Greten

; Petersen

Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33(4): 981–988; 2001.

Dennis

Jr. ; Sherman

B. T.

; Hosack

D. A.

; Yang

; Gao

; Lane

H. C.

; Lempicki

R. A.

DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4(5): P3; 2003.

Dhawan

; Puppi

; Hughes

R. D.

; Mitry

R. R.

Human hepatocyte transplantation: Current experience and future challenges. Nat. Rev. Gastroenterol. Hepatol. 7(5): 288–298; 2010.

10.

Filipski

; Subramanian

; Carriere

; Guettier

; Barbason

; Levi

Circadian disruption accelerates liver carcinogenesis in mice. Mutat. Res. 680(1-2): 95–105; 2009.

11.

Fitzpatrick

; Mitry

R. R.

; Dhawan

Human hepatocyte transplantation: State of the art. J. Intern. Med. 266(4): 339–357; 2009.

12.

Fujino

; Li

X. K.

; Kitazawa

; Funeshima

; Guo

; Okuyama

; Amano

; Amemiya

; Suzuki

Selective repopulation of mice liver after Fas-resistant hepatocyte transplantation. Cell Transplant. 10(4-5): 353–361; 2001.

13.

Gaglio

P. J.

; Liu

; Dash

; Cheng

; Dunne

; Ratterree

; Baskin

; Blanchard

; Bohm

Jr. ; Theise

N. D.

; LaBrecque

Liver regeneration investigated in a non-human primate model (Macaca mulatta). J. Hepatol. 37(5): 625–632; 2002.

14.

Gandillet

; Vidal

; Alexandre

; Audet

; Chenard-Neu

M. P.

; Stutzmann

; Heyd

; Jaeck

; Richert

Experimental models of acute and chronic liver failure in nude mice to study hepatocyte transplantation. Cell Transplant. 14(5): 277–290; 2005.

15.

Grechez-Cassiau

; Rayet

; Guillaumond

; Teboul

; Delaunay

The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J. Biol. Chem. 283(8): 4535–4542; 2008.

16.

Grompe

; Laconi

; Shafritz

D. A.

Principles of therapeutic liver repopulation. Semin. Liver Dis. 19(1): 7–14; 1999.

17.

Guidotti

J. E.

; Mallet

V. O.

; Parlier

; Mitchell

; Fabre

; Jaffray

; Lambert

; Kahn

; Gilgenkrantz

Fas/CD95 pathway induces mouse liver regeneration and allows for highly efficient retrovirus-mediated gene transfer. Hepatology 33(1): 10–15; 2001.

18.

Gupta

; Chowdhury

J. R.

Therapeutic potential of hepatocyte transplantation. Semin. Cell Dev. Biol. 13(6): 439–446; 2002.

19.

Gupta

; Rajvanshi

; Sokhi

; Slehria

; Yam

; Kerr

; Novikoff

P. M.

Entry and integration of transplanted hepatocytes in rat liver plates occur by disruption of hepatic sinusoidal endothelium. Hepatology 29(2): 509–519; 1999.

20.

Haridass

; Yuan

; Becker

P. D.

; Cantz

; Iken

; Rothe

; Narain

; Bock

; Norder

; Legrand

; Wedemeyer

; Weijer

; Spits

; Manns

M. P.

; Cai

; Deng

; Di Santo

J. P.

; Guzman

C. A.

; Ott

Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. Am. J. Pathol. 175(4): 1483–1492; 2009.

21.

Jiang

; Li

J. G.

; Lan

; Wang

Y. M.

; Mao

; You

J. P.

Human hepatoma HepaRG cell line engraftment in severe combined immunodeficient x beige mice using mousespecific anti-Fas antibody. Transplant Proc. 42(9): 3773–3778; 2010.

22.

Kakinuma

; Takagaki

; Yatomi

; Nakamura

; Nagata

; Uemura

; Shibutani

Acute toxicity of an anti-Fas antibody in mice. Toxicol. Pathol. 27(4): 412–420; 1999.

23.

Kawahara

; Douglas

D. N.

; Lewis

; Lund

; Addison

; Tyrrell

D. L.

; Churchill

T. A.

; Kneteman

N. M.

Critical role of natural killer cells in the rejection of human hepatocytes after xenotransplantation into immunodeficient mice. Transpl. Int. 23(9): 934–943; 2010.

24.

Kawahara

; Toso

; Douglas

D. N.

; Nourbakhsh

; Lewis

J. T.

; Tyrrell

D. L.

; Lund

G. A.

; Churchill

T. A.

; Kneteman

N. M.

Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl. 16(8): 974–982; 2010.

25.

Laconi

; Laconi

Principles of hepatocyte repopulation. Semin. Cell Dev. Biol. 13(6): 433–438; 2002.

26.

Lacronique

; Mignon

; Fabre

; Viollet

; Rouquet

; Molina

; Porteu

; Henrion

; Bouscary

; Varlet

; Joulin

; Kahn

Bcl-2 protects from lethal hepatic apoptosis induced by an anti-Fas antibody in mice. Nat. Med. 2(1): 80–86; 1996.

27.

Laemmli

U. K.

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259): 680–685; 1970.

28.

Lee

C. C.

Tumor suppression by the mammalian period genes. Cancer Causes Control 17(4): 525–530; 2006.

29.

Mahieu-Caputo

; Allain

J. E.

; Branger

; Coulomb

; Delgado

J. P.

; Andreoletti

; Mainot

; Frydman

; Leboulch

; Di Santo

J. P.

; Capron

; Weber

Repopulation of athymic mouse liver by cryopreserved early human fetal hepatoblasts. Hum. Gene Ther. 15(12): 1219–1228; 2004.

30.

Matsuo

; Yamaguchi

; Mitsui

; Emi

; Shimoda

; Okamura

Control mechanism of the circadian clock for timing of cell division in vivo. Science 302(5643): 255–259; 2003.

31.

Meuleman

; Libbrecht

; De Vos

; de Hemptinne

; Gevaert

; Vandekerckhove

; Roskams

; Leroux-Roels

Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41(4): 847–856; 2005.

32.

Mitchell

; Mallet

V. O.

; Guidotti

J. E.

; Goulenok

; Kahn

; Gilgenkrantz

Liver repopulation by Bcl-x(L) transgenic hepatocytes. Am. J. Pathol. 160(1): 31–35; 2002.

33.

Mitchell

; Mignon

; Guidotti

J. E.

; Besnard

; Fabre

; Duverger

; Parlier

; Tedgui

; Kahn

; Gilgenkrantz

Therapeutic liver repopulation in a mouse model of hypercholesterolemia. Hum. Mol. Genet. 9(11): 1597–1602; 2000.

34.

; Tomita

; Matsuda

; Ichihara

; Ishimura

; Ogasawara

; Nagata

Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp. Cell Res. 215(2): 332–337; 1994.

35.

Oishi

; Miyazaki

; Kadota

; Kikuno

; Nagase

; Atsumi

; Ohkura

; Azama

; Mesaki

; Yukimasa

; Kobayashi

; Iitaka

; Umehara

; Horikoshi

; Kudo

; Shimizu

; Yano

; Monden

; Machida

; Matsuda

; Horie

; Todo

; Ishida

Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J. Biol. Chem. 278(42): 41519–41527; 2003.

36.

Perera

M. T.

; Mirza

D. F.

; Elias

Liver transplantation: Issues for the next 20 years. J. Gastroenterol. Hepatol. 24(Suppl 3): 124–131; 2009.

37.

Puppi

; Strom

S. C.

; Hughes

R. D.

; Bansal

; Castell

J. V.

; Dagher

; Ellis

E. C.

; Nowak

; Ericzon

B. G.

; Fox

I. J.

; Gomez-Lechon

M. J.

; Guha

; Gupta

; Mitry

R. R.

; Ohashi

; Ott

; Reid

L. M.

; Roy-Chowdhury

; Sokal

; Weber

; Dhawan

Improving the techniques for human hepatocyte transplantation: Report from a consensus meeting in London. Cell Transplant. 21(1): 1–10; 2012.

38.

Richert

; Alexandre

; Lloyd

; Orr

; Viollon-Abadie

; Patel

; Kingston

; Berry

; Dennison

; Heyd

; Mantion

; Jaeck

Tissue collection, transport and isolation procedures required to optimize human hepatocyte isolation from waste liver surgical resections. A multilaboratory study. Liver Int. 24(4): 371–378; 2004.

39.

Roll

G. R.

; Willenbring

Transplanted nonviable human hepatocytes produce appreciable serum albumin levels in mice. Stem Cell Res. 5(3): 267–270; 2010.

40.

Satyanarayana

; Geffers

; Manns

M. P.

; Buer

; Rudolph

K. L.

Gene expression profile at the G1/S transition of liver regeneration after partial hepatectomy in mice. Cell Cycle 3(11): 1405–1417; 2004.

41.

Stockmann

H. B.

; JN

I. J.

Prospects for the temporary treatment of acute liver failure. Eur. J. Gastroenterol. Hepatol. 14(2): 195–203; 2002.

42.

Vidal

; Blanchard

; Alexandre

; Gandillet

; Chenard-Neu

M. P.

; Staedtler

; Schumacher

; Bachellier

; Jaeck

; Firat

; Heyd

; Richert

Improved xenogenic hepatocyte implantation into nude mouse liver parenchyma with acute liver failure when followed by repeated anti-Fas antibody (Jo2) treatment. Cell Transplant. 17(5): 507–524; 2008.

43.

Weglarz

T. C.

; Degen

J. L.

; Sandgren

E. P.

Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am. J. Pathol. 157(6): 1963–1974; 2000.

44.

Weglarz

T. C.

; Sandgren

E. P.

Timing of hepatocyte entry into DNA synthesis after partial hepatectomy is cell autonomous. Proc. Natl. Acad. Sci. USA 97(23): 12595–12600; 2000.

45.

Yamamoto

; Navarro-Alvarez

; Soto-Gutierrez

; Yuasa

; Iwamuro

; Kubota

; Seita

; Kawamoto

; Javed

S. M.

; Kondo

; Noguchi

; Kobayashi

; Nakaji

; Kobayashi

Treatment of acute liver failure in mice by hepatocyte xenotransplantation. Cell Transplant. 19(6): 799–806; 2010.